Pyxis slides after new Phase 1 trial data for lead MICVO option
Pyxis Oncology (PYXS) fell more than 13% in premarket trading after Phase 1 early-stage data for micvotabart pelidotin (MICVO) as a late-line option for certain head and neck carcinoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.